查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1593748

透皮皮膚貼片市場：按類型、按應用、按分銷管道、按地區、機會、預測，2017-2031

Transdermal Skin Patches Market Assessment, By Type, By Application, By Distribution Channel, By Region, Opportunities and Forecast, 2017-2031F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 235 Pages | 商品交期: 3-5個工作天內

價格

2024-2031年預測期間，全球透皮皮膚貼片市場規模將以5.20%的複合年增長率擴大，從2023年的81.2億美元增至2031年的121.8億美元。由於神經系統和心血管疾病等慢性疾病的盛行率不斷上升，預計未來幾年對透皮皮膚貼片的市場需求將呈指數級增長。

透皮皮膚貼片是一種新型藥物傳遞系統。這些系統透過皮膚將藥物輸送給患者，同時允許藥物控制釋放到血液中。皮膚貼片可黏附在患者的皮膚上，並使用多種機制，包括滲透增強劑和微針，將藥物中的活性成分帶入皮膚。與傳統製劑相比，它具有多種優點，例如首過消化和避免胃/酵素藥物降解，從而提高患者依從性、減少副作用並能夠始終維持體內藥物濃度。典型用途包括疼痛管理、荷爾蒙替代和戒菸。

貼片療法的選擇正在不斷擴大，提供更舒適、更有效的治療。對非侵入性藥物傳遞的偏好以及患者依從性和舒適度的提高推動了對透皮皮膚貼片的需求。此外，糖尿病和心血管疾病等慢性疾病的增加增加了對這些貼片的需求，並可能推動全球市場的成長。

本報告考察了全球透皮皮膚貼片市場，並提供了市場概述，包括按類型、應用、分銷管道、區域趨勢以及參與市場的公司概況劃分的趨勢。

目錄

第1章專案範圍與定義

第2章研究方法

第 3 章執行摘要

第 4 章 2017-2031 年全球透皮肌膚貼片市場展望

  • 市場規模分析與預測
  • 市佔率分析與預測
  • 2023 年市場地圖分析
    • 依類型
    • 依用途
    • 按分銷管道
    • 按地區

第5章北美透皮皮膚貼片市場展望，2017-2031

第 6 章歐洲透皮皮膚貼片市場前景，2017-2031

第 7 章亞太地區透皮皮膚貼片市場展望，2017-2031

第8章南美透皮貼片市場前景，2017-2031

第 9 章 2017-2031 年中東及非洲透皮皮膚貼片市場展望

第10章供需分析

第11章價值鏈分析

第12章波特五力分析

第 13 章 PESTLE 分析

第14章價格分析

第 15 章市場動態

第16章市場趨勢與發展

第 17 章監理架構與創新

第18章專利狀況

第 19 章案例研究

第20章競爭態勢

  • 前 5 名市場領導者的競爭矩陣
  • 前 5 名進入公司的 SWOT 分析
  • 市場前10位主要參與者的情況
    • Teva Pharmaceuticals Industries Ltd.
    • Novartis AG
    • Johnson & Johnson Services, Inc.
    • Viatris Inc.
    • Samyang Biopharmaceuticals Corp.
    • Agile Therapeutics Inc.
    • Purdue Pharma L.P.
    • Tiekoku Pharma USA Inc.
    • Hisamitsu Pharmaceutical Co., Inc.
    • Luye Pharma Group
    • Zydus Lifesciences Limited.

第21章策略建議

第22章查詢及免責聲明

Product Code: MX12260

Global transdermal skin patches market is projected to witness a CAGR of 5.20% during the forecast period 2024-2031, growing from USD 8.12 billion in 2023 to USD 12.18 billion in 2031. The market demand for transdermal skin patches is anticipated to thrive drastically in the forecast years due to the rising prevalence of chronic diseases, such as neurological and cardiovascular diseases.

Transdermal skin patches represent novel drug delivery systems. These systems deliver medicine to a patient through the skin while allowing the controlled release of medication into the bloodstream. The skin patches adhere to a patient's skin and draw active ingredients from the agent into the skin by using various mechanisms, including permeation enhancers or microneedles. It shows some advantages over conventional preparations, such as first-pass digestion and avoidance of gastric/enzymatic drug degradation, with better patient compliance, fewer side effects, and always maintaining its drug levels in the body. Some of the primary applications are pain management, replacement of hormones, and smoking cessation.

Patch therapy options are expanding, offering more comfortable and effective treatments. Demand for transdermal patches is driven by the preference for non-invasive drug delivery, improving patient compliance and comfort. Additionally, the rise in chronic diseases like diabetes and cardiovascular conditions is increasing the need for these patches, likely fueling growth in the global market. For instance, in September 2023, Corium, LLC, a biopharmaceutical company, published data reinforcing that ADLARITY (donepezil transdermal system) is a promising transdermal patch with favorable skin adhesion and tolerability. ADLARITY was approved in March 2022 by the United States Food and Drug Administration (US FDA) for the treatment of mild, moderate, and severe dementia of Alzheimer's disease. Donepezil, an acetylcholinesterase inhibitor and the active ingredient in the oral drug Aricept is the most prescribed Alzheimer's dementia medication in the United States.

Increased Demand for Non-Invasive Delivery Brings Market Growth

Rising demand for non-invasive delivery methods significantly drives growth in the transdermal skin patch market. The healthcare sector is increasingly focused on pain-free drug administration, appealing to patients seeking less invasive therapies. Today's patients prefer options that minimize discomfort, avoiding needles or surgical procedures. The healthcare landscape appeals to less painful drug administrations. Patients these days would want therapies that minimize the discomfort and avoid going through some form of surgery or sticking needles into their bodies. These alternatives include transdermal skin patches, comforted by ease of application because they can be self-administered at home without the need for professional assistance. The reasons are particularly pertinent to the case of chronic diseases that require long-term treatment. Patients prefer painless and user-friendly regimens. In addition, non-invasive delivery is less likely to cause complications such as infection or allergic reactions associated with injections. As the healthcare system continues to draw more focus on pain control and patient compliance, there is likely to be greater demand for non-invasive delivery systems that enhance compliance, further fueling the innovation of drug delivery technologies. For instance, in October 2023, Luye Pharma Group received approval for Rivastigmine transdermal patch from China's National Medical Products Administration (NMPA). The patches are proven to be a promising treatment for symptomatic mild to moderate Alzheimer's disease (AD) and have been widely adopted in Europe.

Rising Prevalence of Chronic Diseases

The rising prevalence of chronic diseases is a major growth driver for the transdermal skin patch market, which usually requires long-term management and consistent therapeutic intervention; the growth rate for the transdermal skin patches market is very high. For example, diabetes, hypertension, and chronic pain disorders require precise and effective delivery systems to enhance compliance among patients and ensure optimal health outcomes. The convenience offered through sustained-release medication in transdermal patches is a great solution, as it maintains constant levels of drugs in the bloodstream and decreases the dosing frequency. This is especially attractive to patients on multiple medications or on complex regimens. As the aging population becomes more susceptible to chronic diseases, demand for innovative delivery systems like transdermal skin patches. These patches effectively manage chronic conditions while prioritizing patient comfort and compliance. This trend is expected to drive substantial transdermal skin patch market growth.

A report published by the Shanghai Municipal People's Government highlights chronic disease population among the elderly as a major public health issue in China. The report stated that in 2023, among China's 190 million elderly population, 75% are suffering from at least one chronic condition, while 43% are managing two or more chronic diseases. This underlines the urgent need for health strategies focused on chronic disease management in China's aging population.

Multi-Layer Drug-in-Adhesive Patches to Dominate the Transdermal Skin Patches Market

The multi-layer drug-in-adhesive patches segment is anticipated to assert strong dominance in the transdermal skin patches market. The drug-in-adhesive patches combine various layers of drug and adhesive for prolonged delivery of active ingredients and offer active ingredient stability with less skin irritation, thereby improving patient comfort and compliance. On the rise of personalized treatment options and efficient management of chronic conditions, the versatility and efficiency offered by multilayer drug-in-adhesive patches are ideal for choice among patients and healthcare providers. These are the major factors driving the growth of the transdermal skin patches market.

Moreover, technological advancements and new product launches will further fuel the segment's growth in the market. For instance, in September 2023, Zydus Lifesciences Limited received approval from the United States Food and Drug Administration for Norelgestromin and Ethinyl Estradiol Transdermal System. These patches provide combination hormone medication and are used to prevent pregnancy.

North America Dominates Transdermal Skin Patches Market

North American region is anticipated to dominate the transdermal skin patches market for several reasons, including advanced healthcare infrastructure, a high level of awareness, and the most significant investment in research and development in the region. The strong pharmaceutical sector in the region has played an important role in the innovation and commercialization of new transdermal delivery systems to target the ever-growing demand for efficient and easy forms of treatment. The prevalence of chronic diseases like diabetes and cardiovascular conditions has also pushed the development of safe methods of delivering medication, thereby improving patient compliance. For instance, in August 2024, Zydus Lifesciences Limited received US FDA approval for its Scopolamine Transdermal System, a patch indicated to prevent nausea and vomiting associated with anesthesia, opioid medications, surgery, and motion sickness. The Scopolamine Transdermal System achieved annual sales of USD 69.6 million in the U.S.

Future Market Scenario (2024-2031F)

The future scenario for transdermal skin patches is promising, driven primarily by ongoing technological advancements and evolving healthcare needs. Growing demand for non-invasive drug delivery methods, such as micro needle patches and smart delivery systems, is expected to increase the effectiveness and flexibility of transdermal therapies. The increasing prevalence of chronic diseases and the aging population are likely to drive demand for long-acting products that help improve patient compliance as well as outcomes from therapies. Markets are set to expand into other areas, such as pain management, hormone therapies, and vaccinations, hence driving the growth of the transdermal patches market.

For instance, in January 2024, Starton Therapeutics Inc., a biotechnology company, launched STARSILON, a transdermal patch delivery platform. This adhesive transdermal technology enables continuous, low-dose delivery of various molecules, including those targeting oncology, inflammation, and central nervous system (CNS)conditions. The platform aims to enhance efficacy, reduce toxicity, and improve patient tolerance, opening new opportunities for expanded therapeutic applications.

Key Players Landscape and Outlook

The global transdermal skin patches market is highly competitive, with leading and emerging players vying to capture the elevating opportunities. Market activity reported in recent years includes business agreements, collaborations, and regulatory approvals of market players' products. The market also fosters several smaller players, which operate through collaborations with other players to cater to a larger market.

In August 2024, Agile Therapeutics, Inc. completed the acquisition of Indus Pharma, S.L., a global pharmaceutical group based in Spain. Agile Therapeutics specializes in addressing unmet women's healthcare needs for contraception. Their lead product is Twirla, a prescription contraceptive that delivers levonorgestrel and ethinyl estradiol through a non-daily transdermal patch.

In September 2023, Yaral Pharma Inc. (Yaral Pharma), a subsidiary of Institute Biochimique SA (IBSA), launched Lidocaine Patch 5% for the treatment of pain management and inflammation.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. Global Transdermal Skin Patches Market Outlook, 2017-2031F

  • 4.1. Market Size Analysis & Forecast
    • 4.1.1. By Value
  • 4.2. Market Share Analysis & Forecast
    • 4.2.1. By Type
      • 4.2.1.1. Single-Layer Drug-in-Adhesive Patches
      • 4.2.1.2. Multi-Layer Drug-in-Adhesive Patches
      • 4.2.1.3. Matrix Patches
      • 4.2.1.4. Microneedle Patches
      • 4.2.1.5. Others
    • 4.2.2. By Application
      • 4.2.2.1. Pain Management
      • 4.2.2.2. Hormonal Therapy
      • 4.2.2.3. Cardiovascular Disease
      • 4.2.2.4. Neurological Disorder
      • 4.2.2.5. Smoking Reduction and Cessation Aid
      • 4.2.2.6. Others
    • 4.2.3. By Distribution Channel
      • 4.2.3.1. Hospital Pharmacies
      • 4.2.3.2. Retail Pharmacies
      • 4.2.3.3. Online Pharmacies
      • 4.2.3.4. Others
    • 4.2.4. By Region
      • 4.2.4.1. North America
      • 4.2.4.2. Europe
      • 4.2.4.3. Asia-Pacific
      • 4.2.4.4. South America
      • 4.2.4.5. Middle East and Africa
    • 4.2.5. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2023)
  • 4.3. Market Map Analysis, 2023
    • 4.3.1. By Type
    • 4.3.2. By Application
    • 4.3.3. By Distribution Channel
    • 4.3.4. By Region

5. North America Transdermal Skin Patches Market Outlook, 2017-2031F*

  • 5.1. Market Size Analysis & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share Analysis & Forecast
    • 5.2.1. By Type
      • 5.2.1.1. Single-layer Drug-in-adhesive Patches
      • 5.2.1.2. Multi-layer Drug-in-adhesive Patches
      • 5.2.1.3. Matrix Patches
      • 5.2.1.4. Microneedle Patches
      • 5.2.1.5. Others
    • 5.2.2. By Application
      • 5.2.2.1. Pain Management
      • 5.2.2.2. Hormonal Therapy
      • 5.2.2.3. Cardiovascular Disease
      • 5.2.2.4. Neurological Disorder
      • 5.2.2.5. Smoking Reduction and Cessation Aid
      • 5.2.2.6. Others
    • 5.2.3. By Distribution Channel
      • 5.2.3.1. Hospital Pharmacies
      • 5.2.3.2. Retail Pharmacies
      • 5.2.3.3. Online Pharmacies
      • 5.2.3.4. Others
    • 5.2.4. By Country Share
      • 5.2.4.1. United States
      • 5.2.4.2. Canada
      • 5.2.4.3. Mexico
  • 5.3. Country Market Assessment
    • 5.3.1. United States Transdermal Skin Patches Market Outlook, 2017-2031F*
      • 5.3.1.1. Market Size Analysis & Forecast
        • 5.3.1.1.1. By Value
      • 5.3.1.2. Market Share Analysis & Forecast
        • 5.3.1.2.1. By Type
          • 5.3.1.2.1.1. Single-layer Drug-in-adhesive Patches
          • 5.3.1.2.1.2. Multi-layer Drug-in-adhesive Patches
          • 5.3.1.2.1.3. Matrix Patches
          • 5.3.1.2.1.4. Microneedle Patches
          • 5.3.1.2.1.5. Others
        • 5.3.1.2.2. By Application
          • 5.3.1.2.2.1. Pain Management
          • 5.3.1.2.2.2. Hormonal Therapy
          • 5.3.1.2.2.3. Cardiovascular Disease
          • 5.3.1.2.2.4. Neurological Disorder
          • 5.3.1.2.2.5. Smoking Reduction and Cessation Aid
          • 5.3.1.2.2.6. Others
        • 5.3.1.2.3. By Distribution Channel
          • 5.3.1.2.3.1. Hospitals Pharmacies
          • 5.3.1.2.3.2. Retail Pharmacies
          • 5.3.1.2.3.3. Online Pharmacies
          • 5.3.1.2.3.4. Others
    • 5.3.2. Canada
    • 5.3.3. Mexico

All segments will be provided for all regions and countries covered

6. Europe Transdermal Skin Patches Market Outlook, 2017-2031F

  • 6.1. Germany
  • 6.2. France
  • 6.3. Italy
  • 6.4. United Kingdom
  • 6.5. Russia
  • 6.6. Netherlands
  • 6.7. Spain
  • 6.8. Poland

7. Asia-Pacific Transdermal Skin Patches Market Outlook, 2017-2031F

  • 7.1. India
  • 7.2. China
  • 7.3. Japan
  • 7.4. Australia
  • 7.5. Vietnam
  • 7.6. South Korea
  • 7.7. Indonesia
  • 7.8. Philippines

8. South America Transdermal Skin Patches Market Outlook, 2017-2031F

  • 8.1. Brazil
  • 8.2. Argentina

9. Middle East and Africa Transdermal Skin Patches Market Outlook, 2017-2031F

  • 9.1. Saudi Arabia
  • 9.2. UAE
  • 9.3. South Africa
  • 9.4. Israel

10. Demand Supply Analysis

11. Value Chain Analysis

12. Porter's Five Forces Analysis

13. PESTLE Analysis

14. Pricing Analysis

15. Market Dynamics

  • 15.1. Market Drivers
  • 15.2. Market Challenges

16. Market Trends and Developments

17. Regulatory Framework and Innovation

  • 17.1. Clinical Trials
  • 17.2. Regulatory Approvals

18. Patent Landscape

19. Case Studies

20. Competitive Landscape

  • 20.1. Competition Matrix of Top 5 Market Leaders
  • 20.2. SWOT Analysis for Top 5 Players
  • 20.3. Key Players Landscape for Top 10 Market Players
    • 20.3.1. Teva Pharmaceuticals Industries Ltd.
      • 20.3.1.1. Company Details
      • 20.3.1.2. Key Management Personnel
      • 20.3.1.3. Products and Services
      • 20.3.1.4. Financials (As Reported)
      • 20.3.1.5. Key Market Focus and Geographical Presence
      • 20.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisitions
    • 20.3.2. Novartis AG
    • 20.3.3. Johnson & Johnson Services, Inc.
    • 20.3.4. Viatris Inc.
    • 20.3.5. Samyang Biopharmaceuticals Corp.
    • 20.3.6. Agile Therapeutics Inc.
    • 20.3.7. Purdue Pharma L.P.
    • 20.3.8. Tiekoku Pharma USA Inc.
    • 20.3.9. Hisamitsu Pharmaceutical Co., Inc.
    • 20.3.10. Luye Pharma Group
    • 20.3.11. Zydus Lifesciences Limited.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

21. Strategic Recommendations

22. About Us and Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Transdermal Skin Patches Market, By Value, In USD Billion, 2017-2031F
  • Figure 2. Global Transdermal Skin Patches Market Share (%), By Type, 2017-2031F
  • Figure 3. Global Transdermal Skin Patches Market Share (%), By Application, 2017-2031F
  • Figure 4. Global Transdermal Skin Patches Market Share (%), By Distribution, 2017-2031F
  • Figure 5. Global Transdermal Skin Patches Market Share (%), By Region, 2017-2031F
  • Figure 6. North America Transdermal Skin Patches Market, By Value, In USD Billion, 2017-2031F
  • Figure 7. North America Transdermal Skin Patches Market Share (%), By Type, 2017-2031F
  • Figure 8. North America Transdermal Skin Patches Market Share (%), By Application, 2017-2031F
  • Figure 9. North America Transdermal Skin Patches Market Share (%), By Distribution, 2017-2031F
  • Figure 10. North America Transdermal Skin Patches Market Share (%), By Country, 2017-2031F
  • Figure 11. United States Transdermal Skin Patches Market, By Value, In USD Billion, 2017-2031F
  • Figure 12. United States Transdermal Skin Patches Market Share (%), By Type, 2017-2031F
  • Figure 13. United States Transdermal Skin Patches Market Share (%), By Application, 2017-2031F
  • Figure 14. United States Transdermal Skin Patches Market Share (%), By Distribution, 2017-2031F
  • Figure 15. Canada Transdermal Skin Patches Market, By Value, In USD Billion, 2017-2031F
  • Figure 16. Canada Transdermal Skin Patches Market Share (%), By Type, 2017-2031F
  • Figure 17. Canada Transdermal Skin Patches Market Share (%), By Application, 2017-2031F
  • Figure 18. Canada Transdermal Skin Patches Market Share (%), By Distribution, 2017-2031F
  • Figure 19. Mexico Transdermal Skin Patches Market, By Value, In USD Billion, 2017-2031F
  • Figure 20. Mexico Transdermal Skin Patches Market Share (%), By Type, 2017-2031F
  • Figure 21. Mexico Transdermal Skin Patches Market Share (%), By Application, 2017-2031F
  • Figure 22. Mexico Transdermal Skin Patches Market Share (%), By Distribution, 2017-2031F
  • Figure 23. Europe Transdermal Skin Patches Market, By Value, In USD Billion, 2017-2031F
  • Figure 24. Europe Transdermal Skin Patches Market Share (%), By Type, 2017-2031F
  • Figure 25. Europe Transdermal Skin Patches Market Share (%), By Application, 2017-2031F
  • Figure 26. Europe Transdermal Skin Patches Market Share (%), By Distribution, 2017-2031F
  • Figure 27. Europe Transdermal Skin Patches Market Share (%), By Country, 2017-2031F
  • Figure 28. Germany Transdermal Skin Patches Market, By Value, In USD Billion, 2017-2031F
  • Figure 29. Germany Transdermal Skin Patches Market Share (%), By Type, 2017-2031F
  • Figure 30. Germany Transdermal Skin Patches Market Share (%), By Application, 2017-2031F
  • Figure 31. Germany Transdermal Skin Patches Market Share (%), By Distribution, 2017-2031F
  • Figure 32. France Transdermal Skin Patches Market, By Value, In USD Billion, 2017-2031F
  • Figure 33. France Transdermal Skin Patches Market Share (%), By Type, 2017-2031F
  • Figure 34. France Transdermal Skin Patches Market Share (%), By Application, 2017-2031F
  • Figure 35. France Transdermal Skin Patches Market Share (%), By Distribution, 2017-2031F
  • Figure 36. Italy Transdermal Skin Patches Market, By Value, In USD Billion, 2017-2031F
  • Figure 37. Italy Transdermal Skin Patches Market Share (%), By Type, 2017-2031F
  • Figure 38. Italy Transdermal Skin Patches Market Share (%), By Application, 2017-2031F
  • Figure 39. Italy Transdermal Skin Patches Market Share (%), By Distribution, 2017-2031F
  • Figure 40. United Kingdom Transdermal Skin Patches Market, By Value, In USD Billion, 2017-2031F
  • Figure 41. United Kingdom Transdermal Skin Patches Market Share (%), By Type, 2017-2031F
  • Figure 42. United Kingdom Transdermal Skin Patches Market Share (%), By Application, 2017-2031F
  • Figure 43. United Kingdom Transdermal Skin Patches Market Share (%), By Distribution, 2017-2031F
  • Figure 44. Russia Transdermal Skin Patches Market, By Value, In USD Billion, 2017-2031F
  • Figure 45. Russia Transdermal Skin Patches Market Share (%), By Type, 2017-2031F
  • Figure 46. Russia Transdermal Skin Patches Market Share (%), By Application, 2017-2031F
  • Figure 47. Russia Transdermal Skin Patches Market Share (%), By Distribution, 2017-2031F
  • Figure 48. Netherlands Transdermal Skin Patches Market, By Value, In USD Billion, 2017-2031F
  • Figure 49. Netherlands Transdermal Skin Patches Market Share (%), By Type, 2017-2031F
  • Figure 50. Netherlands Transdermal Skin Patches Market Share (%), By Application, 2017-2031F
  • Figure 51. Netherlands Transdermal Skin Patches Market Share (%), By Distribution, 2017-2031F
  • Figure 52. Spain Transdermal Skin Patches Market, By Value, In USD Billion, 2017-2031F
  • Figure 53. Spain Transdermal Skin Patches Market Share (%), By Type, 2017-2031F
  • Figure 54. Spain Transdermal Skin Patches Market Share (%), By Application, 2017-2031F
  • Figure 55. Spain Transdermal Skin Patches Market Share (%), By Distribution, 2017-2031F
  • Figure 56. Turkey Transdermal Skin Patches Market, By Value, In USD Billion, 2017-2031F
  • Figure 57. Turkey Transdermal Skin Patches Market Share (%), By Type, 2017-2031F
  • Figure 58. Turkey Transdermal Skin Patches Market Share (%), By Application, 2017-2031F
  • Figure 59. Turkey Transdermal Skin Patches Market Share (%), By Distribution, 2017-2031F
  • Figure 60. Poland Transdermal Skin Patches Market, By Value, In USD Billion, 2017-2031F
  • Figure 61. Poland Transdermal Skin Patches Market Share (%), By Type, 2017-2031F
  • Figure 62. Poland Transdermal Skin Patches Market Share (%), By Application, 2017-2031F
  • Figure 63. Poland Transdermal Skin Patches Market Share (%), By Distribution, 2017-2031F
  • Figure 64. South America Transdermal Skin Patches Market, By Value, In USD Billion, 2017-2031F
  • Figure 65. South America Transdermal Skin Patches Market Share (%), By Type, 2017-2031F
  • Figure 66. South America Transdermal Skin Patches Market Share (%), By Application, 2017-2031F
  • Figure 67. South America Transdermal Skin Patches Market Share (%), By Distribution, 2017-2031F
  • Figure 68. South America Transdermal Skin Patches Market Share (%), By Country, 2017-2031F
  • Figure 69. Brazil Transdermal Skin Patches Market, By Value, In USD Billion, 2017-2031F
  • Figure 70. Brazil Transdermal Skin Patches Market Share (%), By Type, 2017-2031F
  • Figure 71. Brazil Transdermal Skin Patches Market Share (%), By Application, 2017-2031F
  • Figure 72. Brazil Transdermal Skin Patches Market Share (%), By Distribution, 2017-2031F
  • Figure 73. Argentina Transdermal Skin Patches Market, By Value, In USD Billion, 2017-2031F
  • Figure 74. Argentina Transdermal Skin Patches Market Share (%), By Type, 2017-2031F
  • Figure 75. Argentina Transdermal Skin Patches Market Share (%), By Application, 2017-2031F
  • Figure 76. Argentina Transdermal Skin Patches Market Share (%), By Distribution, 2017-2031F
  • Figure 77. Asia-Pacific Transdermal Skin Patches Market, By Value, In USD Billion, 2017-2031F
  • Figure 78. Asia-Pacific Transdermal Skin Patches Market Share (%), By Type, 2017-2031F
  • Figure 79. Asia-Pacific Transdermal Skin Patches Market Share (%), By Application, 2017-2031F
  • Figure 80. Asia-Pacific Transdermal Skin Patches Market Share (%), By Distribution, 2017-2031F
  • Figure 81. Asia-Pacific Transdermal Skin Patches Market Share (%), By Country, 2017-2031F
  • Figure 82. India Transdermal Skin Patches Market, By Value, In USD Billion, 2017-2031F
  • Figure 83. India Transdermal Skin Patches Market Share (%), By Type, 2017-2031F
  • Figure 84. India Transdermal Skin Patches Market Share (%), By Application, 2017-2031F
  • Figure 85. India Transdermal Skin Patches Market Share (%), By Distribution, 2017-2031F
  • Figure 86. China Transdermal Skin Patches Market, By Value, In USD Billion, 2017-2031F
  • Figure 87. China Transdermal Skin Patches Market Share (%), By Type, 2017-2031F
  • Figure 88. China Transdermal Skin Patches Market Share (%), By Application, 2017-2031F
  • Figure 89. China Transdermal Skin Patches Market Share (%), By Distribution, 2017-2031F
  • Figure 90. Japan Transdermal Skin Patches Market, By Value, In USD Billion, 2017-2031F
  • Figure 91. Japan Transdermal Skin Patches Market Share (%), By Type, 2017-2031F
  • Figure 92. Japan Transdermal Skin Patches Market Share (%), By Application, 2017-2031F
  • Figure 93. Japan Transdermal Skin Patches Market Share (%), By Distribution, 2017-2031F
  • Figure 94. Australia Transdermal Skin Patches Market, By Value, In USD Billion, 2017-2031F
  • Figure 95. Australia Transdermal Skin Patches Market Share (%), By Type, 2017-2031F
  • Figure 96. Australia Transdermal Skin Patches Market Share (%), By Application, 2017-2031F
  • Figure 97. Australia Transdermal Skin Patches Market Share (%), By Distribution, 2017-2031F
  • Figure 98. Vietnam Transdermal Skin Patches Market, By Value, In USD Billion, 2017-2031F
  • Figure 99. Vietnam Transdermal Skin Patches Market Share (%), By Type, 2017-2031F
  • Figure 100. Vietnam Transdermal Skin Patches Market Share (%), By Application, 2017-2031F
  • Figure 101. Vietnam Transdermal Skin Patches Market Share (%), By Distribution, 2017-2031F
  • Figure 102. South Korea Transdermal Skin Patches Market, By Value, In USD Billion, 2017-2031F
  • Figure 103. South Korea Transdermal Skin Patches Market Share (%), By Type, 2017-2031F
  • Figure 104. South Korea Transdermal Skin Patches Market Share (%), By Application, 2017-2031F
  • Figure 105. South Korea Transdermal Skin Patches Market Share (%), By Distribution, 2017-2031F
  • Figure 106. Indonesia Transdermal Skin Patches Market, By Value, In USD Billion, 2017-2031F
  • Figure 107. Indonesia Transdermal Skin Patches Market Share (%), By Type, 2017-2031F
  • Figure 108. Indonesia Transdermal Skin Patches Market Share (%), By Application, 2017-2031F
  • Figure 109. Indonesia Transdermal Skin Patches Market Share (%), By Distribution, 2017-2031F
  • Figure 110. Philippines Transdermal Skin Patches Market, By Value, In USD Billion, 2017-2031F
  • Figure 111. Philippines Transdermal Skin Patches Market Share (%), By Type, 2017-2031F
  • Figure 112. Philippines Transdermal Skin Patches Market Share (%), By Application, 2017-2031F
  • Figure 113. Philippines Transdermal Skin Patches Market Share (%), By Distribution, 2017-2031F
  • Figure 114. Middle East & Africa Transdermal Skin Patches Market, By Value, In USD Billion, 2017-2031F
  • Figure 115. Middle East & Africa Transdermal Skin Patches Market Share (%), By Type, 2017-2031F
  • Figure 116. Middle East & Africa Transdermal Skin Patches Market Share (%), By Application, 2017-2031F
  • Figure 117. Middle East & Africa Transdermal Skin Patches Market Share (%), By Distribution, 2017-2031F
  • Figure 118. Middle East & Africa Transdermal Skin Patches Market Share (%), By Country, 2017-2031F
  • Figure 119. Saudi Arabia Transdermal Skin Patches Market, By Value, In USD Billion, 2017-2031F
  • Figure 120. Saudi Arabia Transdermal Skin Patches Market Share (%), By Type, 2017-2031F
  • Figure 121. Saudi Arabia Transdermal Skin Patches Market Share (%), By Application, 2017-2031F
  • Figure 122. Saudi Arabia Transdermal Skin Patches Market Share (%), By Distribution, 2017-2031F
  • Figure 123. UAE Transdermal Skin Patches Market, By Value, In USD Billion, 2017-2031F
  • Figure 124. UAE Transdermal Skin Patches Market Share (%), By Type, 2017-2031F
  • Figure 125. UAE Transdermal Skin Patches Market Share (%), By Application, 2017-2031F
  • Figure 126. UAE Transdermal Skin Patches Market Share (%), By Distribution, 2017-2031F
  • Figure 127. South Africa Transdermal Skin Patches Market, By Value, In USD Billion, 2017-2031F
  • Figure 128. South Africa Transdermal Skin Patches Market Share (%), By Type, 2017-2031F
  • Figure 129. South Africa Transdermal Skin Patches Market Share (%), By Application, 2017-2031F
  • Figure 130. South Africa Transdermal Skin Patches Market Share (%), By Distribution, 2017-2031F
  • Figure 131. By Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 132. By Application Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 133. By Distribution Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 134. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023